Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
BEFREE |
We evaluated the potential of two common Type I (273H, contact) and Type II (175H, conformational) TP53 mutations to induce lung tumors in transgenic mice, as well as K-ras status, and other driver mutations in these tumors.
|
30873587 |
2019 |
Lung Neoplasms
|
0.800 |
Biomarker
|
group |
BEFREE |
Lung tumors in old mice displayed higher proliferation rates, as well as attenuated DNA damage and p53 tumor suppressor responses.
|
29047229 |
2018 |
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
BEFREE |
We analyzed the origin of lung tumors in 32 patients with HNSCC using human papillomavirus (HPV) typing and targeted next generation sequencing of all coding exons of tumor protein 53 (TP53).
|
29522268 |
2018 |
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
BEFREE |
Interestingly, p53 co-mutation rendered KRAS<sup>G12C</sup> lung tumors less sensitive to combination treatment with selumetinib and chemotherapy.<b>Conclusions:</b> Our data demonstrate that unique <i>KRAS</i> mutations and concurrent mutations in tumor-suppressor genes are important factors for lung tumor responses to MEK inhibitor.
|
29945997 |
2018 |
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
BEFREE |
Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity.
|
28790158 |
2017 |
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
BEFREE |
They consisted primarily of G to A transition and G to T transversion in both the KRAS (41/56 or 73.2%) and TP53 (24/34 or 70.6%) genes, consistent with mutations found in lung tumors of smoking lung cancer patients.
|
27182622 |
2017 |
Lung Neoplasms
|
0.800 |
Therapeutic
|
group |
CTD_human |
Genomic landscape of cutaneous T cell lymphoma.
|
26192916 |
2015 |
Lung Neoplasms
|
0.800 |
AlteredExpression
|
group |
BEFREE |
At the molecular level, reduced activation of ERK MAPK, but not Akt, was observed in lung tumours of gp130(F/F) mice, and corresponded with impaired expression of several tumour suppressor genes (for example, Trp53, Tsc2).
|
24727895 |
2015 |
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
BEFREE |
Genetic examination revealed mutations in EGFR and p53 that were of the same type as the lung tumor, leading to the final diagnosis of the femoral mass as a sarcomatous transformation of metastatic lung adenocarcinoma.
|
26045851 |
2015 |
Lung Neoplasms
|
0.800 |
AlteredExpression
|
group |
BEFREE |
In this work, we found that PNAS-4 expression in lung tumor tissues is significantly lower than that in adjacent lung tissues; its expression is significantly increased in A549 cells after exposure to cisplatin, methyl methane sulfonate, and mitomycin; and its overexpression induces S phase arrest and apoptosis in A549 (p53 WT), NCI-H460 (p53 WT), H526 (p53 mutation), and Calu-1 (p53(-/-)) lung cancer cells, leading to proliferation inhibition irrespective of their p53 status.
|
25918161 |
2015 |
Lung Neoplasms
|
0.800 |
Biomarker
|
group |
CTD_mouse |
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.
|
26390243 |
2015 |
Lung Neoplasms
|
0.800 |
Biomarker
|
group |
CTD_human |
Genomic landscape of cutaneous T cell lymphoma.
|
26192916 |
2015 |
Lung Neoplasms
|
0.800 |
Biomarker
|
group |
BEFREE |
Herein, we review the epidemiologic connection between tobacco exposure and cancer, the molecular basis of p53 mutation in lung cancer, and the normal molecular and cellular roles of p53 that are abrogated during lung tumor development and progression as defined by in vitro and in vivo studies.
|
24442106 |
2014 |
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
BEFREE |
Our preliminary data showed that LKB1 loss was associated with p53 mutation in lung tumors from Taiwanese adenocarcinoma patients and p53 transcription is directly regulated by NKX2-1.
|
23995788 |
2014 |
Lung Neoplasms
|
0.800 |
Biomarker
|
group |
BEFREE |
Coexpression of siRNA-resistant wild-type, but not mutant, human p53 rescued both IL-17-mediated migration and MMP-9 mRNA induction in p53 knockdown lung tumor cells.
|
25038189 |
2014 |
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
BEFREE |
A total of 189 lung cancer patients were enrolled to determine nickel levels in tumor-adjacent normal lung tissues and p53 mutation status in lung tumors through atomic absorption spectrometry and direct sequencing, respectively.
|
24711049 |
2014 |
Lung Neoplasms
|
0.800 |
Biomarker
|
group |
BEFREE |
We demonstrate proof of concept of this approach by inducing bioluminescent lung tumours in conditional Kras and p53 mice.
|
24307564 |
2014 |
Lung Neoplasms
|
0.800 |
AlteredExpression
|
group |
BEFREE |
In addition, a positive correlation between the expression of p53 and Tpt1 only existed in normal lung tissues, not in lung tumors.
|
24067374 |
2013 |
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
BEFREE |
Furthermore, at the gene level, we identified a rare G>C mutation in TP53, which is uncommon in lung tumors in general (<0.2%) but has been observed in other arsenic-related malignancies.
|
24128716 |
2013 |
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
BEFREE |
We found that four of the variants (rs3829787, rs3841324, rs588765 and rs3743073) were associated with differential levels of genetic alterations measured as the levels of hydrophobic DNA adducts in the adjacent histologically normal tissue of the lung cancer patients and as TP53 mutations in their lung tumors.
|
23011884 |
2013 |
Lung Neoplasms
|
0.800 |
Biomarker
|
group |
BEFREE |
The frequency of p53 protein degradation was also much higher in HPV 16/18 E6-positive/Arg/Arg lung tumors than in the other 3 groups.
|
23522190 |
2013 |
Lung Neoplasms
|
0.800 |
AlteredExpression
|
group |
BEFREE |
Human papillomavirus (HPV) 16/18 E6 oncoprotein is expressed in lung tumors and is associated with p53 inactivation.
|
22982189 |
2012 |
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
BEFREE |
In adjacent histologically normal lung from lung cancer patients (n = 120), low levels of DNA methylation of the CYP1A1 enhancer were related to high levels of smoking-induced hydrophobic DNA adduct (p < 0.03), and to the presence of TP53 or K-ras mutations in the corresponding lung tumors (p < 0.03).
|
22213191 |
2012 |
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
BEFREE |
These findings were validated in breast and lung tumor samples with TP53 mutations.
|
21616106 |
2011 |
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
BEFREE |
The triciribine/tipifarnib synergistic effects are seen with several cancer cell lines including those from breast, leukemia, multiple myeloma and lung tumors with different genetic alterations such as K-Ras, B-Raf, PI3K (phosphoinositide 3-kinase), p53 and pRb mutations, PTEN, pRB and Ink4a deletions, and ErbB receptor overexpression.
|
21536547 |
2011 |